Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

Blood

Volumn 123, Issue 24, 2014, Pages 3733-3738

  Cataland, Spero R ^a   Holers, V Michael ^b   Geyer, Susan ^a   Yang, Shangbin ^c   Wu, Haifeng M ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; ECULIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HOSPITAL DISCHARGE; HUMAN; MALE; MUTATION; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; COMPLEMENT C5A; COMPLEMENT C5B; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84902589905     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-547067     Document Type: Article

References (14)

1. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181.
2. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643-657.
3. Salem G, Flynn JM, Cataland SR. Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol. 2013;92(4):557-558.
4. Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol. 2012;157(4):501-503.
5. Coppo P, Schwarzinger M, Buffet M, et al French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE. 2010;5(4):e10208.
6. Wu TC, Yang S, Haven S, et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2013;11(10):1925-1927.
7. Cataland SR, Wu HM. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur J Intern Med. 2013;24(6):486-491.
8. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol. 2008;141(5):651-658. (Pubitemid 351667632)
9. Caprioli J, Noris M, Brioschi S, et al International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-1279. (Pubitemid 44232024)
10. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. NEngl JMed. 2009;361(17):1676-1687.
11. Réti M, Farkas P, Csuka D, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(5):791-798.
12. Harboe M, Thorgersen EB, Mollnes TE. Advances in assay of complement function and activation. Adv Drug Deliv Rev. 2011;63(12):976-987.
13. Lotta LA, Lombardi R, Mariani M, et al. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. J Thromb Haemost. 2011;9(9):1744-1751.
14. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432-1435. (Pubitemid 13234018)